Singapore Paincare Holdings Provides Update on Subsidiary’s Creditors’ Voluntary Winding-Up

Key Developments

• Voluntary Winding-Up of Subsidiary: Singapore Paincare Holdings Limited (“the Company”) announced a creditors’ voluntary winding-up of its 51% owned subsidiary, Dermatology & Laser Specialist Clinic Pte. Ltd. (“DLS”).
• Shareholder and Creditor Meetings: Both an extraordinary general meeting and a creditors’ meeting were held on 24 February 2026 to formally approve the voluntary winding-up and to confirm the appointments of Tan Wei Cheong and Lim Loo Khoon from Deloitte Singapore SR&T Restructuring Services Pte Ltd as Joint and Several Liquidators of DLS.
• Current Status of Liquidation: As of the date of the announcement, negotiations with creditors have not yet commenced, indicating that the liquidation process is still in its early stages.

Shareholder Impact and Price Sensitivity

• Financial Impact: The Company has stated that the liquidation of DLS is not expected to have any material impact on the net tangible assets or earnings per share of Singapore Paincare Holdings for the current financial year. This suggests that the subsidiary’s operations and financial position were not significant enough within the Group to affect the Company’s overall performance.
• Ongoing Updates: The Company will continue to provide monthly updates and further announcements as required under Catalist Rule 704(22). Shareholders are strongly advised to monitor these updates closely for any new developments that could potentially affect the Company’s financials or market sentiment.
• Caution Advised: Shareholders are specifically advised to refrain from taking any action regarding their securities in the Company that might be prejudicial to their interests. The Company encourages investors to exercise caution when dealing in its shares and to consult professional advisers in case of doubt.

Other Notable Details

• Regulatory Compliance: This announcement has been reviewed by the Company’s sponsor, Novus Corporate Finance Pte. Ltd., but has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”). The SGX-ST assumes no responsibility for the contents of the announcement.
• Contact Information: For further clarification, the sponsor’s contact person is Mr Pong Chen Yih, Chief Operating Officer, located at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.

Summary for Investors

While the winding-up of DLS marks a significant corporate event, management’s confirmation that there will be no material impact on the Group’s net tangible assets or earnings per share should provide some reassurance to investors. Nonetheless, shareholders should remain vigilant for any unforeseen developments during the liquidation process, especially as negotiations with creditors have yet to commence. Continued transparency from the Company through monthly updates will be important for market confidence.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to exercise caution and consult their professional advisers before making any investment decisions. The Singapore Exchange Securities Trading Limited assumes no responsibility for the contents of this article.

View Sing Paincare Historical chart here